GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2009

Merck and DNDi Team Up to Fight Neglected Tropical Diseases

  • Merck & Co. and the Drugs for Neglected Diseases initiative (DNDi) entered into an agreement to support discovery and development of improved treatments for neglected tropical diseases (NTDs). Merck will contribute small molecule assets and related intellectual property via a nonexclusive, royalty-free license to DNDi to conduct early development programs for drug candidates for the treatment of NTDs like visceral leishmaniasis and Chagas disease.

    As part of the collaboration, Merck and DNDi will share joint intellectual property on drug candidates generated through early development. Merck will retain the option to undertake late clinical development and registration of drug candidates at its own expense or in partnership.

     


    ♦♦♦
    Related News

    MMV Takes Over Merck & Co.’s Early-Stage Antimalarial (Mar. 18, 2009)
    Nonprofit Organization Receives License for Anti-HIV Candidate from Merck & Co. (Mar. 11, 2008)



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?